S. Kamal-Bahl

发表

Treatment escalation and rise in HbA1c following successful initial metformin therapy.

G. Nichols, C. Alexander, C. Girman, 2006, Diabetes care.

Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.

N. Wong, Nathan D Wong, Heli Ghandehari, 2008, American heart journal.

Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval

Colby L. Wilkinson, P. Subedi, P. Neumann, 2017, Applied Health Economics and Health Policy.

Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.

N. Wong, S. Kamal-Bahl, H. Ghandehari, 2008, American heart journal.

CHALLENGES FACED IN TRANSFERRING ECONOMIC EVALUATIONS TO MIDDLE INCOME COUNTRIES

M. Drummond, Z. Kaló, F. Augustovski, 2015, International Journal of Technology Assessment in Health Care.

Barriers and solutions to improve access for chimeric antigen receptor therapies.

S. Kamal-Bahl, S. Huntington, J. Puckett, 2022, Immunotherapy.

Defining Value: The Need for a Longer, Broader View

T. Philipson, A. Jena, S. Kamal-Bahl, 2017, PharmacoEconomics.

Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs.

M. Hochberg, B. Briesacher, D. Orwig, 2004, Archives of internal medicine.

Dosage, titration, and gaps in treatment with extended release niacin in clinical practice*

C. Wentworth, D. Watson, T. Burke, 2008, Current medical research and opinion.

Trends in the prescription of inappropriate drugs for the elderly between 1995 and 1999.

J. Doshi, M. Beers, B. Stuart, 2003, The American journal of geriatric pharmacotherapy.

Trends in lipid management among patients with diabetes.

G. Divine, M. Pladevall, L. Williams, 2006, Endocrine Practice.

Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice.

C. Wentworth, D. Watson, T. Burke, 2007, The American journal of cardiology.

Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes

E. Dubberke, J. Doshi, B. Stuart, 2022, Open forum infectious diseases.

Determinants of Youth Tobacco Use in West Virginia: A Comparison of Smoking and Smokeless Tobacco Use

G. Dino, K. Horn, S. Kamal-Bahl, 2000, The American journal of drug and alcohol abuse.

Propoxyphene Use by Community‐Dwelling and Institutionalized Elderly Medicare Beneficiaries

J. Doshi, B. Stuart, B. Briesacher, 2003, Journal of the American Geriatrics Society.

Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review.

J. Doshi, James Campbell, S. Kamal-Bahl, 2002, Archives of pediatrics & adolescent medicine.

Employer-Paid Nonmedical Costs for Patients With Diabetes and End-Stage Renal Disease

C. Alexander, B. Pyenson, S. Kamal-Bahl, 2006, Preventing chronic disease.

The Lifetime Medical Cost Burden of Overweight and Obesity: Implications for Obesity Prevention

E. Finkelstein, J. Trogdon, Eric A. Finkelstein, 2008, Obesity.

Indirect costs of obesity: a review of the current literature

E. Finkelstein, J. Trogdon, S. Kamal-Bahl, 2008, Obesity reviews : an official journal of the International Association for the Study of Obesity.

Contemporary analysis of secondary failure of successful sulfonylurea therapy.

G. Nichols, C. Alexander, C. Girman, 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Propoxyphene use and risk for hip fractures in older adults.

M. Beers, B. Stuart, S. Kamal-Bahl, 2006, The American journal of geriatric pharmacotherapy.

LDL-C goal Attainment Among Patients Newly Diagnosed With Coronary Heart Disease or Diabetes in a Commercial HMO

M. Bullano, C. Alexander, S. Sajjan, 2007, Journal of managed care pharmacy : JMCP.

Obesity, disease burden, and prescription spending by community-dwelling Medicare beneficiaries

B. Stuart, J. Lloyd, S. Kamal-Bahl, 2008, Current medical research and opinion.

Abdominal obesity and the spectrum of global cardiometabolic risks in US adults

N. Wong, S. Kamal-Bahl, S. Bassin, 2009, International Journal of Obesity.

Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis.

Louis P Garrison, Adrian Towse, L. Garrison, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

How do incentive-based formularies influence drug selection and spending for hypertension?

B. Briesacher, S. Kamal-Bahl, 2004, Health affairs.

Financing a Cure for Diabetes in a Multipayer Environment.

Prasun Subedi, Anirban Basu, P. Subedi, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview.

D. Watson, B. Ambegaonkar, S. Kamal-Bahl, 2009, Clinical therapeutics.

The Impact of Physician Attitudes and Beliefs on Treatment Decisions: Lipid Therapy in High-Risk Patients

M. Denke, K. Berra, C. Alexander, 2006, Medical care.

Practical Next Steps in Improving Value Measurement and Use.

D. Ollendorf, S. Kamal-Bahl, P. Gleason, 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.